142 related articles for article (PubMed ID: 23587588)
21. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
Brouard MC; Prins C; Mach-Pascual S; Saurat JH
Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
[TBL] [Abstract][Full Text] [Related]
22. Skin fragility and blistering with imatinib mesylate.
Verma SM; Murphy G
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):496-8. PubMed ID: 19925597
[No Abstract] [Full Text] [Related]
23. Pityriasis rubra pilaris-like reaction induced by imatinib.
Plana A; Carrascosa JM; Vilavella M; Ferrandiz C
Clin Exp Dermatol; 2013 Jul; 38(5):520-2. PubMed ID: 23777493
[TBL] [Abstract][Full Text] [Related]
24. Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
Baskaynak G; Kreuzer KA; Schwarz M; Zuber J; Audring H; Riess H; Dörken B; le Coutre P
Eur J Haematol; 2003 Apr; 70(4):231-4. PubMed ID: 12656746
[TBL] [Abstract][Full Text] [Related]
25. Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia.
Breccia M; Latagliata R; Carmosino I; Mandelli F; Alimena G
Leukemia; 2004 Jan; 18(1):182. PubMed ID: 14574325
[No Abstract] [Full Text] [Related]
26. Imatinib mesylate induced erythroderma.
Sanghavi SA; Dongre AM; Khopkar US
Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
[No Abstract] [Full Text] [Related]
27. Skin fragility and blistering secondary to imatinib.
Reddy H; Horne HL; Maung Z
Clin Exp Dermatol; 2012 Jul; 37(5):572-3. PubMed ID: 22224491
[No Abstract] [Full Text] [Related]
28. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
Deguchi N; Kawamura T; Shimizu A; Kitamura R; Yanagi M; Shibagaki N; Matsue H; Shimada S
Br J Dermatol; 2006 Jun; 154(6):1216-8. PubMed ID: 16704666
[No Abstract] [Full Text] [Related]
29. Follicular mucinosis associated with imatinib (STI571).
Yanagi T; Sawamura D; Shimizu H
Br J Dermatol; 2004 Dec; 151(6):1276-8. PubMed ID: 15606531
[No Abstract] [Full Text] [Related]
30. Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases.
Pascual JC; Matarredona J; Miralles J; Conesa V; Borras-Blasco J
Int J Dermatol; 2006 Dec; 45(12):1471-3. PubMed ID: 17184272
[No Abstract] [Full Text] [Related]
31. Monitoring of imatinib targeted delivery in human leukocytes.
Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
[TBL] [Abstract][Full Text] [Related]
32. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
[TBL] [Abstract][Full Text] [Related]
33. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
Mcpherson T; Sherman V; Turner R
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
[No Abstract] [Full Text] [Related]
34. Oral lichenoid eruption associated with imatinib treatment.
Gómez Fernández C; Sendagorta Cudós E; Casado Verrier B; Feito Rodríguez M; Suárez Aguado J; Vidaurrázaga Díaz de Arcaya C
Eur J Dermatol; 2010; 20(1):127-8. PubMed ID: 19825526
[No Abstract] [Full Text] [Related]
35. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
36. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
37. Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW; O'Brien SG; Ford JM; Druker BJ
J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
[TBL] [Abstract][Full Text] [Related]
38. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
[No Abstract] [Full Text] [Related]
39. Imatinib mesylate-induced neutrophilic folliculitis in a teenager.
García-Romero MT; Durán-McKinster C; de Ocariz MS; Carrasco-Daza D; Palacios-López C; Orozco-Covarrubias L; Ruiz-Maldonado R
Int J Dermatol; 2012 Dec; 51(12):1529-30. PubMed ID: 22486540
[No Abstract] [Full Text] [Related]
40. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]